Search Results 8361-8370 of 42342 for oral

1. Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine - Mayo Clinic

   Previous participation in a clinical study of IV or oral rigosertib. Anemia due to factors other than MDS (including hemolysis or gastrointestinal [GI] ...

2. S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer - Mayo Clinic

   Patients must not be taking oral glucocorticoids at the time of registration. Patients must not be planning to receive concomitant biologic therapy ...

3. A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial To Assess Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Symptomatic Polycystic Liver Disease - Mayo Clinic

   Use of oral contraceptives or estrogen supplementation within 3 months before screening. Poorly controlled diabetes (hemoglobin A1c ≥ 10%) at screening ...

4. A Study To Evaluate The Safety And Effectiveness Of TT-00420 In Adults With Advanced Cholangiocarcinoma - Mayo Clinic

   Inability to swallow or tolerate oral medication. Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the ...

5. Otolaryngology (ENT)/Head and Neck Surgery - Doctors - Mayo Clinic

   l laser microsurgery, Fibula free flap, Microvascular surgery, Oral and throat cancer, Head and neck cancer, Skin cancer, Oropharyngeal cancer, Mouth cancer ...

6. Otolaryngology (ENT)/Head and Neck Surgery - Doctors - Mayo Clinic

   l laser microsurgery, Fibula free flap, Microvascular surgery, Oral and throat cancer, Head and neck cancer, Skin cancer, Oropharyngeal cancer, Mouth cancer ...

7. Phase 2 Study Of VGT-309 In Lung Cancer - Mayo Clinic

   - Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or - Intrauterine device or intrauterine hormone-releasing system

8. 5-strain Probiotic Formulation in Hormone Receptor-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss - Mayo Clinic

   Patients who received oral bisphosphonate within ≤ 12 weeks, IV zoledronic acid (Reclast) ≤ 52 weeks, or denosumab ≤ 24 weeks will also be excluded.

9. A Study to Evaluate Yttrium-90 Therapy for Radiation Lobectomy - Mayo Clinic

   Patients with mild claustrophobia are eligible and have the option to take 1mg oral Lorazepam prior to the MRI, if needed;; Allergy to gadolinium-containing ...

10. A Study of Using Palbociclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive/ Human Epidermal Growth Factor Receptor 2 Negative Early Breast Cancer - Mayo Clinic

    Must be able and willing to swallow and retain oral medication. Serum or urine pregnancy test must be negative in premenopausal women within 14 days of ...